Development of Population PK model building in animal

​

Development of Population PK model building in humans

​

Extrapolation of animal PK to humans (allometric scaling)

​

PK-efficacy, PK-side effects relationship

​

Identify covariates and predictors of exposure (e.g., demographics)

​

Risk-benefit analysis supporting the selection and justification of optimized dose

​

Exposure-QT relationship using Phase I/II data to obtain regulatory waiver

​

End of Phase I/II Population PK and PK-PD to guide dose selection and for design of optimal dose ranging studies

PK-efficacy and PK-adverse event relationship to justify dosing regimen for NDAs

​

Pediatric population PK  modeling  and extrapolation from adults to determine the optimal dose for first pediatric studies and for NDA submissions​

​

Benchmarking and competitor analysis

​

Design, analysis and reporting of studies in different animal species to characterize PK in pre-clinical species and determine the relationship between exposure and toxicity end points (NOEL and NOAEL) or determine the exposure-efficacy or biomarkers. The expertise we provide include:

​

Optimized PK sampling scheme

​

Prediction of safety margins in humans for first-in-man study